ClinicalTrials.gg
Status unknownNCT05093660Updated Apr 7, 2022

Diagnostic Importance of the Circulating Human Leucine-rich α-2-glycoprotein in Acute Appendicitis in Pediatric Patients

An observational study in Appendicitis Acute, sponsored by KBC Split. Status unknown at 1 site in Croatia. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-04-07.

Sponsored by KBC Split · Observational

The sponsor has not verified this record recently (last verified Mar 2022), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
90
Ages
5 Years to 17 Years
Sex
All
01

Study summary

Acute appendicitis is a common and potentially serious medical condition which can be difficult to diagnose, especially in pediatric patients. To help recognize patients with acute appendicitis, number of laboratory and radiological test are used. Previous research has shown that Circulating Human Leucine-rich α-2-glycoprotein (LGR1) in the blood can be elevated in pediatric patients with acute appendicitis. The aim of this research is to analyse whether LGR1 levels in saliva can be used as a less invasive diagnostic method in pediatric patients with suspected acute appendicitis.

02

Conditions studied

  • Appendicitis Acute

Browse trials for

03

In context

Appendicitis

419 studies on the registry are indexed under Appendicitis; 67 are open to participants now.

This study's planned enrollment of 90 is below the median of 200 across 151 observational studies indexed under Appendicitis.

Browse Appendicitis studies →

Lead sponsor

KBC Split is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients from 5 to 17 years of age, presenting with acute abdominal pain consistent with diagnosis of acute appendicitis, to Emergency Surgery Department at the University Hospital Split.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • children with age from 5 do 17 with acute abdominal pain
  • children with clinical signs of appendicitis

Exclusion criteria

Exclusion Criteria:

  • previous diagnosis of chronic and/or malignant disease
  • children which had previous abdominal surgery
  • pregnancy
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
90 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with acute appendicitis

    Patients with acute appendicitis, after surgery and with pathohistological specimen confirmation.

    Diagnostic Test: Blood specimen collection · Diagnostic Test: Saliva specimen collection

  • Patients without acute appendicitis

    Patients without acute appendicitis, after laboratory, clinical and/or radiological exclusion of acute admittance.

    Diagnostic Test: Blood specimen collection · Diagnostic Test: Saliva specimen collection

Interventions

  • Diagnostic testBlood specimen collection

    Blood specimen collection for analysis of CRP (C-reactive protein), WBC (White blood cells) and LRG1 (Circulating Human Leucine-rich α-2-glycoprotein) levels

  • Diagnostic testSaliva specimen collection

    Saliva specimen collection for analysis of LRG1 (Circulating Human Leucine-rich α-2-glycoprotein) levels

06

What researchers measure

Primary outcomes

  1. Level of LGR1 protein in blood

    Levels of LGR1 protein in blood and saliva as measured by ELISA test

    Time frame: 72 hours

  2. Level of LGR1 protein saliva

    Levels of LGR1 protein in saliva as measured by ELISA test

    Time frame: 72 hours

07

Study locations

1 of 1 sites recruiting
  • University Hospital Split
    Split, Splitsko-dalmatinska 21000, Croatia
    Recruiting
    • Zenon Pogorelić, MD, PhD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05093660
Lead sponsor
KBC Split
Responsible party
Goran Tintor (Plastic surgery resident, KBC Split) — Principal investigator
First posted
Oct 26, 2021
Start date
Oct 15, 2021
Primary completion
Jun 30, 2022 (estimated)
Completion
Jun 30, 2022 (estimated)
Last update
Apr 7, 2022

Study contacts

Goran Tintor, MD
Contact
gogitintor@gmail.com
+38521557111

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion